In conclusion, this study indicates that treatment of MPM with intra-pleural IL-2 leads, on one hand to an increase in tryptase-positive MCs, and in CD8+ and Foxp3+ lymphocytes, and on the other hand to an inhibition in tumour-associated vascularity. The gene discussed is IL2; the disease is neoplasm.